HTRF Kinase Assay Development and Methods in Inhibitor Characterization

  • Yong JiaEmail author
  • Mari Manuia
  • Jose Juarez
Part of the Methods in Molecular Biology book series (MIMB, volume 1360)


Due to their important roles in cellular signaling and their dysfunctions being linked to diseases, kinases have become a class of proteins being actively pursued as potential drug targets. Biochemical assays for kinases have been developed in various formats to facilitate inhibitor screening and selectivity profiling. Here, we focus on one such technology: homogeneous time-resolved fluorescence (HTRF). In this chapter, we describe the methods of developing an HTRF kinase assay using mutant EGFR enzyme as an example. We show how to determine the kinetic parameter of the enzyme (ATP Km), as well as how to study the inhibitor mechanism of action (MoA) exemplified by inhibitors of different MoAs. All methods described here can be readily applied to other kinases with minor modifications.

Key words

HTRF TR-FRET Kinase Assay development MoA studies Inhibitor characterization 


  1. 1.
    Manning G, Whyte DB, Martinez R et al (2002) The protein kinase complement of the human genome. Science 298:1912–1934CrossRefPubMedGoogle Scholar
  2. 2.
    Cohen P (1999) The development and therapeutic potential of protein kinase inhibitors. Curr Opin Chem Biol 3:459–465CrossRefPubMedGoogle Scholar
  3. 3.
    Hunter T (2000) Signaling—2000 and beyond. Cell 100:113–127CrossRefPubMedGoogle Scholar
  4. 4.
    Paez JG, Janne PA, Lee JC et al (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304:1497–1500CrossRefPubMedGoogle Scholar
  5. 5.
    Pao W, Girard N (2011) New driver mutations in non-small-cell lung cancer. Lancet Oncol 12:175–180CrossRefPubMedGoogle Scholar
  6. 6.
    Soda M, Choi YL, Enomoto M et al (2007) Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer. Nature 448:561–566CrossRefPubMedGoogle Scholar
  7. 7.
    Davies H, Bignell GR, Cox C et al (2002) Mutations of the BRAF gene in human cancer. Nature 417:949–954CrossRefPubMedGoogle Scholar
  8. 8.
    Fabbro D, Garcia-Echeverria C (2002) Targeting protein kinases in cancer therapy. Curr Opin Drug Discov Dev 5:701–712Google Scholar
  9. 9.
    Myers MR, He W, Hulme C (1997) Inhibitors of tyrosine kinases involved in inflammation and autoimmune disease. Curr Pharm Des 3:473–502Google Scholar
  10. 10.
    Minor L (2005) Assays for membrane tyrosine kinase receptors: methods for high-throughput screening and utility for diagnostics. Expert Rev Mol Daign 5:561–571CrossRefGoogle Scholar
  11. 11.
    Sittampalam GS, Kahl SD, Janzen WP (1997) High-throughput screening: advances in assay technologies. Curr Opin Chem Biol 1:384–391CrossRefPubMedGoogle Scholar
  12. 12.
    Zaman GJR, Garritsen A, de Boer TH et al (2003) Fluorescence assays for high-throughput screening of protein kinases. Comb Chem High Throughput Screen 6:313–320CrossRefPubMedGoogle Scholar
  13. 13.
    von Ahsen O, Bömer U (2005) High-throughput screening for kinase inhibitors. Chem Bio Chem 6:481–490CrossRefGoogle Scholar
  14. 14.
    Jia Y, Gu X, Brinker A et al (2008) Measuring the tyrosine kinase activity: a review of biochemical and cellular assay technologies. Expert Opin Drug Discov 3:959–978CrossRefPubMedGoogle Scholar
  15. 15.
    Jia Y, Quinn CM, Kwak S et al (2008) Current in vitro kinase assay technologies: the quest for a universal format. Curr Drug Discov Technol 5:59–69CrossRefPubMedGoogle Scholar
  16. 16.
    Zegzouti H, Zdanovskaia M, Hsiao K, Goueli SA (2009) ADP-Glo: A bioluminescent and homogeneous ADP monitoring assay for kinases. Assay Drug Dev Technol 7:560–572CrossRefPubMedGoogle Scholar
  17. 17.
    Mathis G (1999) HTRF technology. J Biomol Screen 4:309–313CrossRefPubMedGoogle Scholar
  18. 18.
    Mathis G (1995) Probing molecular interactions with homogeneous techniques based on rare earth cryptates and fluorescence energy transfer. Clin Chem 41:1391–1397PubMedGoogle Scholar
  19. 19.
    Mathis G (1993) Rare earth cryptate and homogeneous fluoroimmunoassays with human sera. Clin Chem 39:1953–1959PubMedGoogle Scholar
  20. 20.
    Kobayashi S, Boggon TJ, Dayaram T et al (2005) EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352:786–792CrossRefPubMedGoogle Scholar
  21. 21.
    Pao W, Miller VA, Politi KA et al (2005) Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2, e73PubMedCentralCrossRefPubMedGoogle Scholar
  22. 22.
    Yun C-H, Boggon TJ, Li Y et al (2007) Structure of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell 11:217–227PubMedCentralCrossRefPubMedGoogle Scholar
  23. 23.
    Jia Y, Quinn CM, Gagnon AI (2006) Homogeneous time-resolved fluorescence and its applications for kinase assays in drug discovery. Anal Biochem 356:273–281CrossRefPubMedGoogle Scholar
  24. 24.
    Hong L, Quinn CM, Jia Y (2009) Evaluating the utility of the HTRF Transcreener™ ADP assay technology: A comparison with the standard HTRF assay technology. Anal Biochem 391:31–38CrossRefPubMedGoogle Scholar
  25. 25.
    Li D, Ambrogio L, Shimamura T et al (2008) BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 27:4702–4711PubMedCentralCrossRefPubMedGoogle Scholar
  26. 26.
    Moyer JD, Barbacci EG, Iwata KK et al (1997) Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res 57:4838–4848PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  1. 1.Genomics Institute of the Novartis Research FoundationSan DiegoUSA

Personalised recommendations